Dabrafenib + Trametinib

DRUG7 trials

Sponsors

Universitair Ziekenhuis Brussel, Novartis Pharmaceuticals, Sun Yat-sen University, Saint Petersburg State University, Russia, West China Hospital

Conditions

Anaplastic Thyroid CancerBRAF V600 MutationFertilityLocally Advanced Thyroid Gland CarcinomaMET Exon 14 MutationMalignant MelanomaMelanomaNSCLC

Phase 2

Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients

CompletedNCT02296996

Universitair Ziekenhuis BrusselMalignant Melanoma

Start: 2014-10-31End: 2017-12-31Updated: 2019-01-23

Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations

Not yet recruitingNCT06054191

Sun Yat-sen UniversityBRAF V600 Mutation, MET Exon 14 Mutation, NSCLC

Start: 2024-02-01End: 2027-03-01Target: 40Updated: 2023-10-10

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

RecruitingNCT06362694

Saint Petersburg State University, RussiaAnaplastic Thyroid Cancer

Start: 2024-03-25End: 2026-06-25Target: 10Updated: 2024-04-12

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

RecruitingNCT06482086

West China HospitalLocally Advanced Thyroid Gland Carcinoma

Start: 2021-06-01End: 2025-12-01Target: 75Updated: 2024-12-05

Unknown Phase

Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

CompletedNCT04547946

Novartis PharmaceuticalsMalignant Melanoma

Start: 2021-10-15End: 2022-06-07Updated: 2023-05-30

Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

CompletedNCT05714371

Novartis PharmaceuticalsMelanoma

Start: 2021-10-02End: 2022-01-27Updated: 2023-02-06

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

RecruitingNCT07092670

Intergruppo Melanoma ItalianoFertility, Melanoma

Start: 2025-08-04End: 2032-08-31Target: 270Updated: 2025-09-05

Related Papers

Precision treatment guided by patient-derived organoids-based drug testing for locally advanced thyroid cancer: a single arm, phase 2 study.

2025-04-303 citations

128TiP A phase II, two parallel group study of neoadjuvant and adjuvant targeted treatment in NSCLC with BRAF V600 or MET exon 14 mutations

ESMO Open2024-03-011 citations

Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF<sup>V600</sup>-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial.

2017-03-04119 citations